Background: We studied the effect of statins on mortality in a nationally representative sample of patients with multiple myeloma, and explored the benefit of statins in a subgroup of patients treated with novel agents.
Methods: Patients diagnosed with multiple myeloma between 2007 and 2013 were identified in the SEER-Medicare database using International Classification of Diseases (ICD)-03 codes. ICD-9 and Healthcare Common Procedure Coding System codes were used to identify comorbidities and treatments. We assessed the association of statins with mortality in patients with multiple myeloma using multivariate Cox proportional hazards regression analysis. For subanalysis, we used the same statistical technique to investigate the effect of statins on mortality in myeloma patients treated with novel agents.
Results: A total of 5922 patients were diagnosed with multiple myeloma within the study period. Use of statins was associated with 21% reduction in risk of death (adjusted hazard ratio [aHR] 0.79; 95% confidence interval [CI] 0.74-0.84) among all patients with multiple myeloma. Among the patents treated with novel agents (n = 3603), statins reduced mortality by 10% (aHR = 0.90, 95% CI 0.83-0.98).
Conclusions: Use of statins is likely associated with lower mortality in patients with multiple myeloma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2020.07.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extramedullary plasmacytoma is rare, it can appear alone or associated with multiple myeloma, representing an extramedullary progression of the disease. We present the case of a 62-year-old woman diagnosed with multiple myeloma who, being in complete remission began to experience abdominal pain and nausea. A rare cause of intestinal subocclusion and upper gastrointestinal bleeding.
View Article and Find Full Text PDFA Retrospective Analysis of Morbidity and Risk Factors of Multiple Myeloma with Peripheral Neuropathy.
Br J Hosp Med (Lond)
December 2024
Department of Hematology, Hebei General Hospital, Shijiazhuang, Hebei, China.
Peripheral nerve injury affects some people with multiple myeloma; this condition can be brought on by the disease itself or by the treatments they receive. Such a complication increases patients' financial burden, causes treatment to be interrupted or delayed, and reduces treatment efficacy. However, opinions regarding the risk factors for peripheral neuropathy are currently divided.
View Article and Find Full Text PDFHip Hemiarthroplasty in Patients with Multiple Myeloma: A Retrospective Case Series and Review of the Literature.
Rev Bras Ortop (Sao Paulo)
February 2025
Departamento de Cirurgia Ortopédica, Geisinger Medical Center, Danville, PA, Estados Unidos.
Femoral neck fractures in multiple myeloma patients are usually managed with hemiarthroplasty or total hip arthroplasty, depending on the presence of acetabular infiltration. Due to the paucity of dedicated studies, the aim of the present study is to review the clinical outcomes of hip hemiarthroplasty in patients with multiple myeloma and to review the literature regarding the outcomes and survival in these patients' subset. There were 15 patients (16 cases), with a mean age of 71.
View Article and Find Full Text PDFPeriorbital necrobiotic xanthogranuloma resolved with three years of systemic lenalidomide treatment.
Am J Ophthalmol Case Rep
March 2025
Ophthalmic Surgeons and Consultants of Ohio, Columbus, OH, USA.
Purpose: To describe a case report of the successful management of necrobiotic xanthogranuloma (NXG), a rare periorbital disease.
Observations: A 61-year-old patient presented with bilateral upper and lower lid lesions which were initially misdiagnosed as xanthelasmas and later confirmed to be NXG. Further investigation also uncovered a diagnosis of multiple myeloma.
Refining High-Risk Multiple Myeloma: Advancements in Genomic, Clinical, and Prognostic Criteria.
Mediterr J Hematol Infect Dis
January 2025
Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Multiple myeloma (MM) is a heterogeneous disease, with MM patients experiencing different clinical outcomes depending on the disease's biological features. Novel insights into the molecular mechanisms of MM have led to the introduction of sophisticated drugs, which dramatically improved patient treatment and survival. To date, young patients with newly diagnosed MM could experience a median overall survival (OS) of 10 years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!